News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Metabolic fitness platform Ultrahuman acquires consumer-focused wearable company LazyCo

Ultrahuman

Ultrahuman, the world’s most advanced metabolic fitness platform, has today announced the acquisition of consumer-focused wearable company LazyCo famed for creating the Aina ring wearable. LazyCo will integrate with Ultrahuman’s global in-house hardware development team as they seek opportunities to enhance the user experience and help improve global metabolic health standards. Ultrahuman will leverage the LazyCo team’s expertise to generate deeper metabolic insights and better overall health insights for consumers. The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better. Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome diversity, stress levels, time of the day, food ingredient quality, etc. With this acquisition, the idea would be to expand the set of real-time biomarkers that could provide unique health insights upon correlation. LazyCo was founded by engineers turned product designers, Apoorv Shankar and Yogansh Namdeo in 2017. The company focused on building hardware products that made daily life easier. One of the notable products included the Aina Ring - an AI-powered smart ring designed to predict and automate daily tasks without the need to take the phone out of the pocket. Digital tasks such as booking cabs, controlling smart home devices, activating SOS alerts, and taking phone calls, were 7x faster and easier through the ring. LazyCo completed a successful Kickstarter campaign in 2019 and won several design and startup awards from the likes of Alibaba and Qualcomm. “Ultrahuman’s vision of making health more personalized and impactful for people syncs with LazyCo’s vision of building products that solve problems for people in the most effortless ways. Together, we can create a deeper impact on the overall health of the world,” said Apoorv Shankar, Co-Founder and CEO, LazyCo. Ultrahuman launched with a wearable (the “Ultrahuman M1”) - a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day. It triggers timely nudges to the user such as alerts to a high blood glucose event and suggestions to take a walk for optimizing their glucose levels. “We want to make it easy to get healthy. At Ultrahuman, we’re deep believers in passive personalized health, specifically in a health platform that requires very minimal effort from a user’s perspective. This perfectly aligns with the philosophy of LazyCo.” said Mohit Kumar, Founder and CEO, Ultrahuman. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). There, he observed athletes train smartly via the usage of data, recovery tools and protocols. He got together with Vatsal and they came up with a vision for Ultrahuman where they can make the journey of fitness for people more personalized and impactful. Ultrahuman is a venture-backed startup that has raised $25m to date. Their investors include Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of marquee founders and angel investors including Tiger Global’s Scott Schleifer. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. By using glucose and other biomarkers, Ultrahuman is helping people improve their energy levels, lose fat and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

April 12, 2022 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University

Q-Vant Biosciences

Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed a Master Agreement with Kansas State University’s College of Veterinary Medicine to test and evaluate its saponin-based adjuvants in several of the university’s veterinary vaccines. Among the most highly regarded universities in the nation for veterinary vaccine science, K-State is home to the Biosecurity Research Institute, a world-renowned high-security containment facility. The Master Agreement will benefit Q-VANT and the university. The first project under the agreement will compare Q-VANT’s 100% sustainable saponin-based adjuvants to other known adjuvants utilizing K-State’s subunit classic swine fever (CSF) vaccine. This study will further the university’s instructional and research project objectives while advancing its vaccine development program. For Q-VANT, the study will serve to validate the safety and efficacy of the company’s Quillaja saponin-based adjuvants. “We’re excited to be working with Kansas State University and are looking forward to demonstrating the safety and efficacy of our adjuvants for widespread use in the global veterinary pharmaceutical market. The CSF field trial is the first of many we hope to perform with K-State using our 100% sustainable saponin-based adjuvants,” said Q-VANT’s Chief Commercial Officer, Juan Jose Allbarran. The CSF vaccine was developed by K-State professor Dr. Jishu Shi. Dr. Shi also serves as the director of the U.S.-China/Asia Center for Animal Health, where he and his team are working on novel vaccine and diagnostic strategies that are aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF) and other emerging viral diseases of swine. “This partnership is an exciting opportunity for all involved,” said Dr. Shi. “Our students will have the opportunity to take part in a research project that has the potential to have a major positive impact globally in animal vaccine development and usage.” About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company's next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 times - enabling the production of billions of doses annually to meet today's increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Hillary Lima +1 401-490-9700 q-vant@svmpr.com Company Website https://q-vant.com/

April 12, 2022 08:00 AM Eastern Daylight Time

Article thumbnail News Release

CORRECTING and REPLACING Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

In the last sentence boilerplate of release dated April 11, 2022, "multiple accolated and awards" corrected to read "multiple awards". The updated release reads: Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 12:24 PM Eastern Daylight Time

Article thumbnail News Release

Cannabis Education Event to Inform and Empower Consumers

MCR Labs

Local cannabis testing laboratory MCR Labs is hosting a consumer education event aimed at empowering consumers with the knowledge they need to make informed decisions about their cannabis purchases and consumption choices. The event, which is free and open to the public, will feature a presentation by MCR’s Vice President of Scientific Development Scott Churchill and InhaleMD’s President & CEO Dr. Jordan Tishler. Dr. Tishler is a Cannabinoid Specialist. “There is a lot of speculation out there on terms like ‘Total Active Cannabinoids’ and how factors like shelf life stability affect product quality,” said Churchill. “Our goal here is to help consumers develop a deeper understanding of cannabis so they can choose the right product for themselves.” MCR Labs provides analytical cannabis testing services to cultivators and product manufacturers. The data produced by these services, such as cannabinoid content, is often advertised on product labels. “It’s really important that patients understand how compounds like cannabinoids interact with their bodies,” said Dr. Tishler. “This can help them understand their medicine and work with their healthcare professionals to achieve optimal treatment.” Through his training in Internal Medicine and years of practice as an Emergency Physician, Dr. Tishler brings his knowledge, reason, and caring to patients at inhale MD, and through his advocacy work at the local and national levels. “What’s In Your Weed: The Educated Consumer” will be held this Thursday, April 14 from 6 to 8 p.m. at District Hall in Boston. Anyone interested in learning more or attending the event can find details on the event website. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

April 11, 2022 11:08 AM Eastern Daylight Time

Article thumbnail News Release

Fine Hygienic Holding Continues to Lead on Progressive Female-Friendly Workplace Reforms with Pregnancy Loss Policy

Fine Hygienic Holding

Fine Hygienic Holding (FHH), the world-leading wellness group and manufacturer of hygienic paper products and long-term germ protection solutions, has yet again taken the initiative to introduce new female-friendly policies as part of its continuous workplace reforms which aim to provide the most inclusive and welcoming environment possible for all its employees. Demonstrating that the company is serious about bringing about positive change, it has updated its Parental Leave Policy to include provisions for miscarriage or stillbirth, across all its locations. FHH already has generous maternity leave provisions for working mothers who benefit from 16 weeks of paid leave, above what the International Labour Organization recommends, and it even offers 3 weeks of paid paternity leave, which puts it at the forefront not only in the MENA region but also globally. Employees are eligible for compassionate leave upon the unfortunate event of a female employee or a male employee’s spouse suffering a miscarriage or stillbirth. In both instances the employee is entitled to five days of paid leave, and females may take an additional five days of unpaid leave. This comes in line with FHH’s core values to lead with empathy and extend leave to women needing time to recover physically and emotionally, and to consider the needs of male partners as well. No other company in the region offers such a generous leave policy, with provisions for maternity, paternity, miscarriage or stillbirth, in addition to a monthly day off for females. James Michael Lafferty, FHH CEO, said, “Our company believes that – if we take care of the people, the business will take care of itself – which is why we are constantly on the lookout for practices that support our employees’ wellbeing, especially during pivotal moments in their lives. With our updated policy our aim is to live our values and support our employees through difficult times.” FHH adheres to the highest standards of HR practices with a strong emphasis on supporting and empowering parents within its workforce. It is worth mentioning that the company was recently recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Fine Hygienic Holding (FHH), one of the world’s leading wellness groups and MENA’s leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. Committed to becoming “the shining star of the Arab FMCG business world,” the Group focuses on wellness, sustainability, pioneering CSR programs, and state-of-the-art production processes. Fine Hygienic Holding offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings Nai natural iced teas and innovative nutritional supplements, Motiva, to the market. Along with multiple accolated and awards over the years, particularly for its products and CSR initiatives, the company was recognized as a Top Employer Middle East 2022 by the prestigious Top Employers Institute in every country it operates. Contact Details Rana Kawalit | │ Corporate Communication & PR Director Rkawalit@finehh.com Company Website https://www.finehh.com/

April 11, 2022 02:59 AM Eastern Daylight Time

Article thumbnail News Release

Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke

Ninnion

Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics, today announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. It would be the first drug of its kind in the treatment of stroke, potentially making it eligible for Breakthrough Therapy designation by the FDA, a designation that can accelerate the development timeline. “Ninnion saw a big opportunity to develop NIN-S119, as there are no approved drug therapies for patients recovering from a stroke. It will be used in conjunction with physical/occupational therapy to enhance stroke recovery by inducing neuroplasticity – meaning it induces the formation of new connections between nerve cells in the brain. This sort of brain ‘rewiring’ could prove beneficial for stroke recovery by creating new brain circuitry that could restore function to brain areas damaged by stroke,” said Bill W Massey, Chief Development Officer of Ninnion. While drugs of this class that produce neuroplastic effects can induce psychedelic experiences (e.g. LSD, mescaline, DMT, etc.), one major benefit of NIN-S119 is that even though it's in this class of drugs, it could potentially be administered in low doses that do not produce these experiences. This would make NIN-S119 much easier to use clinically, reducing the time and effort of clinical staff and opening the potential for administration by the patient at home. “After experiencing multiple health issues, including three strokes in one year, I began researching and reading all about how to repair the brain through the neuroplasticity and neurogenesis effects of psychedelics. We created Ninnion to not only develop a new way to treat strokes but more importantly, to bring these drugs to market in a responsible way. The way psychedelic therapies are set up now is not helpful for the payer-reimbursed market. We want to create therapies that are accessible and affordable; patients should not have to pay thousands of dollars for therapies out of pocket. We’re encouraged by recent patent approvals for the development and delivery of new psychedelic therapies and we’re looking forward to advancing our clinical trials and continuing to develop other molecules in our pipeline,” said Jeremy M Caudill, Founder, and CEO of Ninnion. Ninnion’s research and development efforts currently focus on advancing next-generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities. To find out more about the study and Ninnion’s NIN-S119 molecule, visit www.ninnion.com/. About Ninnion Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com. Contact Details Jive PR + Digital Ashley Areeda +1 734-891-4013 aareeda@jiveprdigital.com

April 07, 2022 11:33 AM Eastern Daylight Time

Article thumbnail News Release

COD Mammography Program Acquires Cutting-Edge, Hospital-Grade Equipment

College of DuPage

Mammography program students at College of DuPage now have access to more specialized training, thanks for the addition of new field-specific equipment. The innovative digital technology, Hologic Tomosynthesis 2D and 3D mammography machines, typically are available at hospitals and clinical settings and rarely on a college campus, said COD Diagnostic Medical Imaging Assistant Professor and Mammography Program Chair Sue Dumford. “The new equipment gives students an added advantage to be able to practice their skills in the classroom before having to use it on real patients during clinical rotations at hospitals and clinics,” she said. “Students will be able to practice on other classmates as well as on model torsos with soft breasts. Having the machines in front of students also allows us to teach about quality assurance and quality control.” The Mammography program at COD is a one-semester post-radiography advanced certificate program available to graduates of an accredited Radiography program. Many of the students enrolled in the Mammography program are graduates of COD’s two-year Radiography program. "I’m proud to say that we maintain a 100 percent American Registry of Radiologic Technologists registry pass rate and that our graduates are recognized as excellent entry-level mammographers,” Dumford said. Tara Logan decided to pursue a career in mammography after working at the front desk of a general surgery office. “One of the doctors in my office was a breast surgeon,” she said. “Every day he worked with breast cancer patients, and I will never forget how he made them feel. When people are going through some of the toughest days of their life, they need someone to lean on, and I wanted to be that person for them.” Logan graduated from COD’s Radiography program in 2020 earning an Associate in Applied Science in Diagnostic Medical Imaging before earning an advanced certificate in Mammography in 2021. “The program truly prepared me for a long career in breast imaging, and I’m so lucky to have been a part of both COD’s Radiography and Mammography programs,” she said. “With the two mammography units, I was able to learn correct positioning skills and then go out into the field and practice on real patients. Cancer screening is something that will always be needed, and your patients will always need you. Apply to the program and start making a difference in the way females feel about health care.” Learn more about the COD Mammography program. Learn more about COD’s Radiography program. Contact Details College of DuPage Angela Mennecke +1 630-942-3134 menneckea@cod.edu

April 07, 2022 08:00 AM Central Daylight Time

Image
Article thumbnail News Release

Cloudrise Is Taking 2022 By Storm

Cloudrise

Cloudrise Inc., a technology-enabled services firm focused on data protection, cloud security, and privacy, continues to make waves with a flurry of exciting news to kick-off 2022. Cloudrise is pleased to announce the acquisition of CyberOrchard, an information security managed service organization located in the United Kingdom. Cloudrise CEO, Rob Eggebrecht, shared his thoughts: “The merger of the two companies brings a breadth of knowledge and expertise to Cloudrise, paving the way to expand our portfolio of data protection services to the global market.” As part of the acquisition, Jason Bird, CyberOrchard’s Founder and CEO, has been named Chief Technology Officer (CTO) at Cloudrise. Bird has over 25 years of experience in cybersecurity, managed services, data governance, and privacy. “Data protection is becoming more complex every day, and at Cloudrise we believe collaboration is the path to better protection for our customers. We are partnering with the strongest data-centric technology companies to bring innovative solutions to our customers, such as Netskope, AWS, Digital Guardian, Microsoft, OneTrust, Varonis, BigID, and Veritas, just to name a few,” said Bird. This news comes just a week after Netskope named Cloudrise as their Global Services Partner of the Year. “This achievement illustrates Cloudrise’s commitment to delivering innovative service offerings to customers worldwide,” said Joe Infantino, Chief Operating Officer at Cloudrise. Additionally, Cloudrise is pleased to announce that CRN®, a brand of The Channel Company, has named Cloudrise to its Managed Service Provider (MSP) 500 list in the Managed Security 100 category for 2022. Winners are recognized for helping end users increase efficiency, simplify solutions, and maximize their return on investment. Cloudrise is taking 2022 by storm and encourages its followers to stay tuned for future announcements. About Cloudrise Cloudrise is a technology-enabled services firm, specializing in delivering data-centric services customized to meet organizations’ business needs. Drawing from 20+ years of experience in the field, they have tailored their services to be focused on securing organizations’ data wherever it resides. Cloudrise knows how to identify gaps, build and optimize controls and integrations across the enterprise, and deploy data-centric technologies across multiple industries, geographies and organizational sizes – all with the expertise to navigate an ever-changing data compliance and regulatory landscape. Cloudrise can be found at Cloudrise.com or on LinkedIn. About CyberOrchard UK-based CyberOrchard is an information security managed services organization, home to experts with over 20 years of data security experience. Whether the risk to organizations' data lives in transit on the network, at rest in storage, or in use at an endpoint, CyberOrchard provides the necessary data security bundled service offerings, consultancy and managed services to significantly reduce organizations' risk of data loss. CyberOrchard can be found at cyberorchard.com or on LinkedIn. Contact Details Jodi Lewis +1 800-917-7619 sales@cloudrise.com Company Website https://cloudrise.com/

April 06, 2022 07:00 AM Mountain Daylight Time

Article thumbnail News Release

Lancer Dermatology Announces Partnership with Forefront Dermatology

Lancer

Premier Beverly Hills-based dermatology practice, Lancer Dermatology, announced today that it has partnered with Forefront Dermatology, the largest physician-led single specialty group providing dermatological services in the United States with over 200+ dermatology practices. The collaboration with Forefront Dermatology will serve to expand the world-renowned legacy of the Lancer Dermatology practice through satellite clinics in select additional markets across the United States. Since opening the clinic in 1983, Dr. Harold Lancer has grown his Beverly Hills-based dermatology practice into a world-renowned mecca with a celebrity cult-following. Currently, the practice is a global destination for celebrities, socialites, and even members of royal families. Dr. Lancer’s work ethic, integrity, approach, and results make him one of the most sought-out dermatology professionals, piquing the interest of Forefront Dermatology. The team at Lancer Dermatology consists of tenured nurses and skilled aestheticians who have been personally trained by Dr. Lancer to deliver the highest level of service and care to their patients. The partnership between Lancer Dermatology and Forefront Dermatology will allow the legacy and state-of-the-art care that Lancer Dermatology is known for worldwide, to expand beyond the Beverly Hills clinic for many years to come. By opening satellite locations across the nation, even more patients will be able to experience the state-of-the-art care that Lancer Dermatology is celebrated for, even if they are unable to visit the Beverly Hills practice. “The highlight of my career was when I opened the doors to my Beverly Hills clinic in 1983, and every day since then I have had the pleasure of treating my patients with unparalleled care. I am proud to partner with Forefront Dermatology to extend the legacy we have created at Lancer Dermatology to make our state-of-the-art experience and treatments even more accessible,” said Dr. Harold Lancer, Board-Certified Dermatologist and Founder of Lancer Dermatology and Lancer Skincare. “For many years, we have had the goal to extend the state-of-the-art approach of Lancer Dermatology practice beyond the Beverly Hills clinic. When Forefront Dermatology approached our team, it was clear that their preeminent expertise in expansion was in perfect alignment with our goals. Through this partnership, we are thrilled to be expanding our legacy, without sacrificing on quality of care,” said Tracey Sameyah, CEO of Lancer Skincare. “Our partnership with Dr. Lancer and the Lancer Dermatology Team is consistent with our approach to partnering with Board-Certified Dermatologists and Surgeons that are committed to physician leadership, innovation, and exceptional patient experiences and outcomes. We are thrilled to partner with Dr. Lancer on expanding access to dermatology care and leveraging the expertise and strong reputation he has garnered over the past 30 years,” said Betsy J. Wernli, MD, President of Forefront Dermatology. The Beverly Hills clinic will remain unaffected by the partnership, with no changes being made to the day-to-day operations or existing staff of distinguished nurses and aestheticians. Dr. Lancer’s international skincare brand, Lancer Skincare, will also remain a separate entity, owned solely by Dr. Lancer, with no changes to the award-winning products that bring to life his philosophy of “from practice to product.” Lancer Dermatology is moving faster than ever to make its state-of-the-art care and approach more accessible and available to everyone. For more information about Lancer Dermatology, please visit LancerSkincare.com or @drlancerrx. About Lancer Dermatology The goal at Lancer Dermatology is to provide each patient with expert skin care and a personalized, first-class experience. Lancer Dermatology offers state-of-the-art care in aesthetic, cosmetic, medical and surgical dermatology treatments. The Lancer Dermatology team consists of tenured nurses who have been personally trained by Dr. Lancer to deliver the highest level of service and care to our patients. Dr. Lancer believes that the best way to foster trust and commitment amongst patients is to have a knowledgeable and familiar team at his side. The Lancer Nursing Team is an elite and talented group of professionals who are always on hand to assist with all patient consultations and procedures. Dr. Lancer's skilled aestheticians possess decades of experience providing customized services and treatments to patients. Trained by Dr. Lancer himself, the aesthetician team is comprised of multilingual, highly-professional and sought-after experts who are proficient in The Lancer Method protocols as well as all of the Services & Technologies offered exclusively at the Lancer Dermatology Clinic. With revolutionized procedures and tools, the team is able to provide a personalized, best-in-class experience to every patient. About Forefront Dermatology Located throughout the East, Midwest, Mid-Atlantic, Southwest, Southeast and West, Forefront Dermatology is a large and growing, physician-led, single-specialty group practice comprising 200+ dermatology practices. Forefront's community-based, Board-Certified Dermatologists and specialists provide best-in-class general, surgical and cosmetic dermatological care along with related laboratory services. Headquartered in Manitowoc, WI, Forefront's Board-Certified Dermatologists and medical specialists are dedicated to providing the highest standard of care for conditions of the hair, skin, and nails to people of all ages and stages of life. Using innovative and proven solutions, Forefront's caring, Board-Certified Dermatologists and medical specialists treat the total patient to help improve not only the condition of their skin, but also their quality of life. To learn more, visit www.ForefrontDermatology.com. Contact Details OGAKI Malinda Torres +1 646-475-7056 mtorres@ogakidigital.com Company Website https://www.lancerskincare.com/

April 04, 2022 09:00 AM Eastern Daylight Time

1 ... 189190191192193 ... 249